8-K: Kala Bio Faces Nasdaq Delisting Warning After Bid Price Drop

Kala Bio, Inc. received a delisting warning from Nasdaq due to its common stock closing below $1.00 for 30 consecutive days, and is ineligible for a standard compliance period.

Summary

• Kala Bio, Inc. (the Company) received a notification from Nasdaq on August 27, 2026, stating it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• The Company's common stock has closed below $1.00 for 30 consecutive business days, from July 16, 2026, through August 26, 2026.
• Unlike typical cases, Kala Bio is not eligible for the standard 180-day compliance period because it executed a reverse stock split (1-for-50) on May 11, 2026, within the past year.
• The Company plans to request a hearing before the Nasdaq Hearings Panel to appeal this determination.
• There is no guarantee that the appeal will be successful or that the Company will regain compliance with listing requirements.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the company's non-compliance with Nasdaq listing rules and ineligibility for a standard compliance period, indicating significant financial or operational challenges.

Negatives

• The company is not in compliance with Nasdaq's minimum bid price requirement ($1.00) for continued listing.
• The company's common stock has traded below $1.00 for 30 consecutive business days (July 16, 2026 August 26, 2026).
• Kala Bio is ineligible for the standard 180-day compliance period due to a recent reverse stock split (1-for-50 on May 11, 2026).
• There is uncertainty regarding the outcome of the appeal to the Nasdaq Hearings Panel and the ability to regain compliance.

Risks

• Potential delisting from The Nasdaq Capital Market if the appeal is unsuccessful or compliance is not regained.
• Continued low stock price may reflect underlying business or financial concerns.
• The outcome of the Nasdaq Hearings Panel decision is uncertain.
• Failure to meet continued listing requirements could impact investor confidence and stock liquidity.

Future Outlook

The company intends to request a hearing before the Nasdaq Hearings Panel to appeal the determination. There can be no assurance that the company's request for continued listing will be granted or that it will be able to regain and maintain compliance with the Minimum Bid Price Requirement or all other applicable requirements for continued listing on The Nasdaq Capital Market.

Management Comments

• "There can be no assurance that the Company's request for continued listing will be granted or that the Company will be able to regain and maintain compliance with the Minimum Bid Price Requirement or all other applicable requirements for continued listing on The Nasdaq Capital Market."

Industry Context

StockSavvy.ai notes that Nasdaq listing rules are designed to ensure a minimum level of market capitalization and investor interest. Failure to meet these standards, especially after a reverse stock split, often signals underlying financial distress or a lack of market confidence, which is a common concern for smaller biotechnology companies.

Stakeholder Impact

• Shareholders: Potential for decreased stock value and liquidity if delisted; uncertainty surrounding future trading.
• Creditors: May view the company as higher risk due to potential delisting and financial instability.
• Employees: Potential impact on morale and job security if delisting leads to financial difficulties.

Next Steps

• Request a hearing before the Nasdaq Hearings Panel to appeal the Staff's determination.
• Attempt to regain compliance with the Minimum Bid Price Requirement and other Nasdaq listing rules.

Key Dates

Recommendation

The filing indicates a critical compliance failure with Nasdaq listing rules, making the company ineligible for a standard cure period due to a recent reverse stock split. This situation, coupled with the uncertainty of a successful appeal, significantly increases the risk of delisting, which would likely lead to a substantial decline in stock value and liquidity. This warrants a sell recommendation.

Keywords

Nasdaq delisting, minimum bid price, continued listing, reverse stock split, Nasdaq Hearings Panel, compliance, stock price